This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Kumar SK, Lee JH, Lahuerta JJ, Morgan G, Richardson PG, Crowley J, et al. Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study. Leukemia. 2012;26:149–57.
San Miguel J, Weisel K, Moreau P, Lacy M, Song K, Delforge M. et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055–66.
Siegel DS, Martin T, Wang M, Vij R, Jakubowiak AJ, Lonial S, et al. A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma. Blood. 2012;120:2817–25.
Hájek R, Masszi T, Petrucci MT, Palumbo A, Rosiñol L, Nagler A, et al. A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS). Leukemia. 2017;31:107–14.
Cavo M, Tacchetti P, Patriarca F, Petrucci MT, Pantani L, Galli M, et al. Bortezomib with thalidomide plus dexamethasone compared with thalidomide plus dexamethasone as induction therapy before, and consolidation therapy after, double autologous stem-cell transplantation in newly diagnosed multiple myeloma: a randomised phase 3. Lancet. 2010;376:2075–85.
Richardson PG, Xie W, Jagannath S, Jakubowiak A, Lonial S, Raje NS, et al. A phase 2 trial of lenalidomide, bortezomib, and dexamethasone in patients with relapsed and relapsed/refractory myeloma. Blood. 2014;123:1461–9.
Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, Špička I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142–52.
Shah JJ, Stadtmauer EA, Abonour R, Cohen AD, Bensinger WI, Gasparetto C, et al. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma. Blood. 2015;126:2284–90.
Berenson JR, Cartmell A, Bessudo A, Lyons RM, Harb W, Tzachanis D, et al. CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma. Blood. 2016;127:3360–8.
Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497–503.
Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide-refractory multiple myeloma: Intergroupe Francophone du Myélome 2009–02. Blood. 2013;121:1968–75.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hájek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17(1):27–38.
Acknowledgements
The authors thank the patients who participated in the source trials, the nurses Carina Pusceddu and Cristina M. Russo, the data managers Antonella Fiorillo and Jessica Mastrovito, and Ugo Panzani and Giorgio Schirripa for assistance in preparation and submission of the paper.
Author contributions
S.B., R.M., A.P., P.S., and M.B. designed the study and supervised its conduct and the data analysis; S.B., R.M., A.M.C., A.M.L., A.B., G.G., F.P., R.F., L.D.P., G.R., A.L., P.B., and M.B recruited patients in the source studies and provided relevant data; S.B., R.M., R.T. collected, assembled, and analyzed the data; S.S. performed the statistical analysis; S.B. and R.M. drafted the initial manuscript; and all authors were given unrestricted access to the data, critically reviewed the manuscript drafts, approved the final version, and made the decision to submit the manuscript for publication.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
S.B. has received honoraria from Celgene, Janssen, BMS, Amgen; Advisory board for Janssen and Amgen; consultancy fees from Takeda; G.G. has served on the advisory boards for Roche, AbbVie, Janssen, Gilead, and Morphosys; F.P. has received lecturing fees from MSD Italia and served on the advisory board for Janssen; L.D.P. has served on the advisory boards for AbbVie, Amgen, Celgene, and Janssen; G.R. has served on the advisory boards for Celgene and Amgen; A.P. is currently a Takeda employee; P.S. has received research support from Amgen, Celgene, Janssen, Karyopharm, and honoraria from Amgen, Celgene, Janssen, Karyopharm and BMS; and M.B. has received research funding from Amgen, BMS, Celgene, Janssen, Mundipharma, Novartis, Sanofi, and honoraria from AbbVie, Amgen, BMS, Celgene, Janssen, Novartis, Sanofi. The remaining authors declare that they have no conflict of interest.
Additional information
Antonio Palumbo: Currently Takeda employee.
Electronic supplementary material
Rights and permissions
About this article
Cite this article
Bringhen, S., Mina, R., Cafro, A.M. et al. Once-weekly carfilzomib, pomalidomide, and low-dose dexamethasone for relapsed/refractory myeloma: a phase I/II study. Leukemia 32, 1803–1807 (2018). https://doi.org/10.1038/s41375-018-0024-1
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41375-018-0024-1
This article is cited by
-
The changing landscape of relapsed and/or refractory multiple myeloma (MM): fundamentals and controversies
Biomarker Research (2022)
-
Gaps and opportunities in the treatment of relapsed-refractory multiple myeloma: Consensus recommendations of the NCI Multiple Myeloma Steering Committee
Blood Cancer Journal (2022)
-
Multiple myeloma current treatment algorithms
Blood Cancer Journal (2020)
-
KRD (carfilzomib and lenalidomide plus dexamethasone) for the treatment of relapsed or refractory multiple myeloma in the real-life: a retrospective survey in 123 patients
Annals of Hematology (2020)
-
Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study
Blood Cancer Journal (2019)